Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -6933.56% is 46% above its 4-year average of -12917.03%, near the high end of its 4-year range (-110573.33%–306.44%).
37.96% above its 12-month average of -11175.66%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2018 (2018-09-30): -10396.36%.
EBITDA MARGIN
-6933.56%
EBITDA MARGIN AVG TTM
-11175.66%
EBITDA MARGIN AVG 3Y
-13934.22%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+37.96%
CURRENT VS 3Y AVG
+50.24%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tempest Therapeutics, Inc.
Market Cap
$12.58M
EBITDA Margin
-6933.56%
TTM Avg
-11175.66%
3Y Avg
-13934.22%
5Y Avg
N/A
Market Cap
$12.48M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$12.44M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$12.78M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$12.06M
EBITDA Margin
-16245.70%
TTM Avg
-13416.38%
3Y Avg
-13330.05%
5Y Avg
-20098.17%
Market Cap
$13.20M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.93M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. (TPST) | $12.58M | -6933.56% | -11175.66% | -13934.22% | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | -34.02% | -37.67% | -64.98% | -56.41% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | -16245.70% | -13416.38% | -13330.05% | -20098.17% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.93M | -19.85% | -31.46% | -46.77% | -56.23% |
| Optimi Health Corp. (OPTH)vs › | $13.30M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
Gross Margin
0.0%
EBITDA Margin
-6933.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2018-09-30 | -10396.36% |
| 2018-06-30 | -9540.74% |
| 2018-03-31 | -10823.88% |
| 2017-12-31 | -8963.74% |
| 2017-09-30 | -16153.57% |
| 2017-06-30 | -18390.48% |
| 2017-03-31 | -20060.32% |
| 2016-12-31 | -17995.87% |
| 2016-09-30 | -9332.99% |
| 2016-06-30 | -9353.44% |
| 2016-03-31 | -14339.04% |
| 2015-12-31 | -12549.04% |
| 2015-09-30 | -23245.33% |
| 2015-06-30 | -56636.67% |
| 2015-03-31 | -110573.33% |
| 2014-12-31 | 306.44% |
